S.R. Schill & Associates’s Novartis NVS Stock Holding History

S.R. Schill & Associates’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,252	Closed	-$250K	–	80
2018 Q4	$250K	Buy	+3,252	New	+$253K	0.18%	71

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

S.R. Schill & Associates's NVS Position: Q1 2019 in Review

S.R. Schill & Associates sold out of Novartis (NVS) in Q1 2019, closing a stake of 3,252 shares — an estimated $250K sold.

S.R. Schill & Associates first reported a position in NVS in Q4 2018 and held it in 1 quarter. The position peaked at $250K in Q4 2018. 1,134 funds tracked by Wall St. Rank hold NVS as of Q1 2019.

S.R. Schill & Associates reported no remaining Novartis position as of Q1 2019 after selling out during the quarter.
S.R. Schill & Associates sold 3,252 Novartis shares in Q1 2019, an estimated $250K.
S.R. Schill & Associates first reported a position in Novartis in Q4 2018 and held it in 1 quarter.
S.R. Schill & Associates's Novartis position peaked at $250K in Q4 2018.
1,134 funds tracked by Wall St. Rank held Novartis as of Q1 2019.

Based on S.R. Schill & Associates's 13F filing for Q1 2019, filed 2 May 2019.